Literature DB >> 2966552

Acute hemodynamic effects of intravenous isradipine.

E K van den Berg1, G J Dehmer.   

Abstract

The acute hemodynamic effects of isradipine, a new dihydropyridine calcium antagonist, were evaluated in 16 men referred for elective cardiac catheterization. Low-dose (0.007 mg/kg, n = 8) and high-dose (0.015 mg/kg, n = 8) isradipine was administered intravenously over 10 minutes and the hemodynamic alterations assessed 10 minutes after completion of infusion. Low-dose isradipine caused increases in heart rate (68 +/- 9 to 79 +/- 12 beats/min, p less than 0.001) (mean +/- standard deviation), cardiac index (3.0 +/- 0.7 to 4.1 +/- 0.9 liter/min/m2, p less than 0.001) and coronary sinus blood flow (114 +/- 27 to 162 +/- 74 ml/min, p less than 0.01), and significant decreases in mean aortic pressure (104 +/- 17 to 92 +/- 10 mm Hg, p less than 0.01), systemic and coronary vascular resistance. High-dose isradipine caused similar effects: the heart rate increased (72 +/- 6 to 84 +/- 14 beats/min, p less than 0.005), as did the cardiac index (3.0 +/- 0.6 to 4.6 +/- 0.9 liter/min/m2, p less than 0.001) and coronary sinus blood flow (122 +/- 48 to 166 +/- 47 ml/min, p less than 0.025). In addition, there were increases in the stroke volume index (43 +/- 10 to 55 +/- 8 ml/m2, p less than 0.001) and left ventricular stroke work index (69 +/- 12 to 79 +/- 12 g-m/m2, p = 0.05) after the high-dose infusion. Vascular resistance declined significantly in the systemic, pulmonary and coronary beds.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2966552     DOI: 10.1016/0002-9149(88)90134-8

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

Review 1.  Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

2.  Acute haemodynamic effects of isradipine in hypertensive heart transplant recipients.

Authors:  H Aass; S Simonsen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 3.  Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.